GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sequent Scientific Ltd (NSE:SEQUENT) » Definitions » Debt-to-EBITDA

Sequent Scientific (NSE:SEQUENT) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sequent Scientific Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sequent Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Sequent Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Sequent Scientific's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹1,601 Mil. Sequent Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sequent Scientific's Debt-to-EBITDA or its related term are showing as below:

NSE:SEQUENT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.49   Med: 3.01   Max: 59.34
Current: 3.18

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sequent Scientific was 59.34. The lowest was -8.49. And the median was 3.01.

NSE:SEQUENT's Debt-to-EBITDA is ranked worse than
69.31% of 681 companies
in the Drug Manufacturers industry
Industry Median: 1.62 vs NSE:SEQUENT: 3.18

Sequent Scientific Debt-to-EBITDA Historical Data

The historical data trend for Sequent Scientific's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequent Scientific Debt-to-EBITDA Chart

Sequent Scientific Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.28 1.34 3.09 -8.49 9.15

Sequent Scientific Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 4.08 - 3.11 -

Competitive Comparison of Sequent Scientific's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Sequent Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequent Scientific's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sequent Scientific's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sequent Scientific's Debt-to-EBITDA falls into.


;
;

Sequent Scientific Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sequent Scientific's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3158.77 + 1718.16) / 533.17
=9.15

Sequent Scientific's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 1601.2
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Sequent Scientific  (NSE:SEQUENT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sequent Scientific Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sequent Scientific's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequent Scientific Business Description

Traded in Other Exchanges
Address
Plot No. E7, Road No. 22, 301, 3rd Floor, Dosti Pinnacle, Wagle Industrial Estate, Thane (West), Mumbai, MH, IND, 400 604
Sequent Scientific Ltd is a pharmaceutical company operating animal health and analytical services. It develops API products and formulations. The company's product portfolio includes products across various therapy classes such as antibiotics, anthelmintics, pain management, and nutrition. The company's geographical segment includes Europe, Asia, and Rest of the world. It generates maximum revenue from Europe.

Sequent Scientific Headlines

No Headlines